1. Home
  2. FHN vs TGTX Comparison

FHN vs TGTX Comparison

Compare FHN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Horizon Corporation

FHN

First Horizon Corporation

HOLD

Current Price

$23.34

Market Cap

12.3B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$58.11

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FHN
TGTX
Founded
1864
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3B
8.5B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
FHN
TGTX
Price
$23.34
$58.11
Analyst Decision
Buy
Strong Buy
Analyst Count
19
5
Target Price
$26.24
$49.80
AVG Volume (30 Days)
4.3M
1.6M
Earning Date
04-15-2026
05-04-2026
Dividend Yield
2.79%
N/A
EPS Growth
37.50
1746.67
EPS
1.07
0.17
Revenue
$3,419,000,000.00
$2,785,000.00
Revenue This Year
$7.57
$49.08
Revenue Next Year
$4.07
$26.69
P/E Ratio
$22.36
$336.24
Revenue Growth
7.18
N/A
52 Week Low
$19.80
$26.76
52 Week High
$26.56
$59.30

Technical Indicators

Market Signals
Indicator
FHN
TGTX
Relative Strength Index (RSI) 37.10 61.27
Support Level $23.62 $51.76
Resistance Level $25.10 $58.12
Average True Range (ATR) 0.41 2.10
MACD -0.04 0.15
Stochastic Oscillator 22.97 78.74

Price Performance

Historical Comparison
FHN
TGTX

About FHN First Horizon Corporation

First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets. The Wholesale segment delivers industry-specific products and services, while the Corporate segment provides internal support functions like finance, risk, and audit.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: